search
Back to results

A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers

Primary Purpose

Venous Thromboembolism

Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
ONO-7684
ONO-7684 Placebo
Sponsored by
Ono Pharmaceutical Co. Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Venous Thromboembolism

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. 18-55 years
  2. normotensive male volunteers, or female volunteers of non-childbearing potential (Part B only)
  3. body mass index 18.0-30.0 kg/m2
  4. deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine
  5. registered with a General Practitioner (GP) in the UK
  6. agree to use an effective method of contraception
  7. able to give fully informed written consent

Exclusion Criteria:

  1. Positive tests for hepatitis B & C, HIV
  2. severe adverse reaction to any drug
  3. sensitivity to trial medication
  4. drug or alcohol abuse
  5. current smoker or use of nicotine containing products in the previous 6 months
  6. vegetarians or vegans, or unwilling to eat a high-fat breakfast (Part A food effect cohorts only)
  7. use of strong CYP3A4/5 or P-glycoprotein inhibitors or inducers, anticoagulants, antiplatelet agents, non-steroidal anti-inflammatory drugs and/or acetylsalicylic acid within the previous 30 days
  8. prescription or over-the-counter medication, vitamins, herbal treatments or dietary supplements within the previous 7 days (with the exception of paracetamol [acetaminophen])
  9. participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the previous 3 months or plan to donate blood or blood products in the 3 months after the trial
  10. vital signs outside the acceptable range
  11. clinically relevant abnormal findings at the screening assessment (including creatinine clearance, haemoglobin levels and QTcF)
  12. acute or chronic illness
  13. clinically relevant abnormal medical history or concurrent medical condition
  14. objection by GP
  15. possibility that volunteer will not cooperate
  16. pre-menopausal females who are pregnant or lactating, or who are of childbearing potential

Sites / Locations

  • Hammersmith Medicines Research (HMR)

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

ONO-7684 Part A1

ONO-7684 Placebo Part A1

ONO-7684 Part A2

ONO-7684 Placebo Part A2

ONO-7684 Part B1

ONO-7684 Placebo Part B1

Arm Description

Single ascending doses of ONO-7684 or placebo orally under fasted conditions

Single ascending doses of ONO-7684 or placebo orally under fasted conditions

Single doses of ONO-7684 or placebo orally under fed conditions

Single doses of ONO-7684 or placebo orally under fed conditions

Eligible subjects will receive multiple doses of ONO-7684 or placebo orally

Eligible subjects will receive multiple doses of ONO-7684 or placebo orally

Outcomes

Primary Outcome Measures

Number of participants with clinically significant changes in vital signs (Part A & B)
Pulse rate (bpm), systolic and diastolic blood pressure (mmHg), Respiratory rate (bpm)
Number of participants with clinically significant changes observed on 12-lead electrocardiogram (ECG) (Part A & B)
Ventricular rate (beats/min), PR interval (msec), QRS interval (msec), QT (msec), QTcF interval (msec)
Number of participants with clinically significant changes in cardiac telemetry (Part A only)
Number of participants with cardiac telemetry abnormalities will be reported.
Number of participants with clinically significant changes in physical examination (Part A & B)
Number of participants with physical examination abnormalities will be reported.
Number of participants with clinically significant changes in laboratory safety tests (haematology, biochemistry and urinalysis) (Part A & B)
Number of participants with abnormalities in laboratory safety tests will be reported.
Number of participants with adverse events (AE) (Part A & B)
AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Secondary Outcome Measures

Pharmacokinetics (Cmax)
Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Pharmacokinetics (tmax)
Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Pharmacokinetics (AUClast)
Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Pharmacokinetics (AUCinf)
Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Pharmacokinetics (AUCt)
Assessment of the area under the curve of concentration of ONO-7684 and 3-hydroxybenzoic acid - time from zero up to a definitive time, t in Parts A and B
Pharmacokinetics (%AUCextrap)
Assessment of the percentage of AUC∞ extrapolated from tlast to infinity of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Pharmacokinetics (t1/2)
Assessment of the elimination half-time of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Pharmacokinetics (CL/F)
Assessment of the apparent clearance rate of ONO-7684 and 3-hydroxybenzoic acid in Part A only
Pharmacokinetics (Terminal Rate Constant)
Assessment of the terminal rate constant (slowest rate constant of the disposition) of ONO-7684 and 3-hydroxybenzoic acid in plasma in Part A only
Pharmacokinetics (Aet)
Assessment of the amount of ONO-7684 excreted in urine over the period of sample collection in Part A only
Pharmacokinetic (fe/F)
Assessment of the fraction of orally administered ONO-7684 excreted into urine in Part A only
Pharmacokinetic (CLr)
Assessment of the renal clearance of ONO-7684 from plasma in Part A only
Pharmacokinetic (Ctrough)
Assessment of the trough plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Part B only
Pharmacokinetic (AUCtau)
Assessment of the area under the plasma concentration of ONO-7684 and 3-hydroxybenzoic acid -time during a dosing interval in Part B only
Pharmacokinetic (CLSS/F)
Assessment of total clearance of ONO-7684 from plasma after oral administration in Part B only
Pharmacokinetic (VZ/F)
Assessment of apparent volume of distribution of ONO-7684 after non-intravenous administration calculated at steady state in Part B only
Pharmacodynamic (change from baseline in aPTT activity) in serum
Assessment of the effect of ONO-7684 in activated partial thromboplastin time in Parts A and B
Pharmacodynamic (change from baseline in PT activity) in serum
Assessment of the effect of ONO-7684 in prothrombin time in Parts A and B
Pharmacodynamic (change from baseline in PT-INR activity) in serum
Assessment of the effect of ONO-7684 in prothrombin time-international normalised ratio in Parts A and B
Pharmacodynamic (change from baseline in FXIa activity) in serum
Assessment of the effect of ONO-7684 in blood coagulation activated factor XI in Parts A and B
Pharmacodynamic (correlation of aPTT and FXIa activity) in serum
Assessment of the effect of ONO-7684 in the correlation of activated partial thromboplastin time to blood coagulation activated factor XI in Parts A and B

Full Information

First Posted
March 14, 2019
Last Updated
December 6, 2019
Sponsor
Ono Pharmaceutical Co. Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT03919890
Brief Title
A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers
Official Title
A First-in-human, Randomised, Placebo-controlled, Double-blind, Single and Multiple Dose Study to Explore the Safety, Tolerability, PK and PD of Oral Doses of ONO-7684 in Healthy Subjects Under Fed and Fasted Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
January 17, 2019 (Actual)
Primary Completion Date
August 23, 2019 (Actual)
Study Completion Date
August 23, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ono Pharmaceutical Co. Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a first in human study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ONO-7684 in healthy adult volunteers. This study will be conducted in 2 parts: Part A is a single-ascending dose and Part B is a multiple-ascending dose.
Detailed Description
This study aims to obtain safety, tolerability, pharmacokinetic and pharmacodynamic data when ONO-7684 is administered orally as single doses and as multiple doses to healthy subjects. The study will consist of 2 parts: A single ascending dose (SAD) phase (Part A); a multiple ascending dose (MAD) phase (Part B). One cohort of Part A will receive ONO-7684 under both fasted and fed conditions to investigate the effect of food.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Thromboembolism

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
ParticipantInvestigator
Masking Description
Double-blinded
Allocation
Randomized
Enrollment
72 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ONO-7684 Part A1
Arm Type
Experimental
Arm Description
Single ascending doses of ONO-7684 or placebo orally under fasted conditions
Arm Title
ONO-7684 Placebo Part A1
Arm Type
Placebo Comparator
Arm Description
Single ascending doses of ONO-7684 or placebo orally under fasted conditions
Arm Title
ONO-7684 Part A2
Arm Type
Experimental
Arm Description
Single doses of ONO-7684 or placebo orally under fed conditions
Arm Title
ONO-7684 Placebo Part A2
Arm Type
Placebo Comparator
Arm Description
Single doses of ONO-7684 or placebo orally under fed conditions
Arm Title
ONO-7684 Part B1
Arm Type
Experimental
Arm Description
Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
Arm Title
ONO-7684 Placebo Part B1
Arm Type
Placebo Comparator
Arm Description
Eligible subjects will receive multiple doses of ONO-7684 or placebo orally
Intervention Type
Drug
Intervention Name(s)
ONO-7684
Intervention Description
Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
Intervention Type
Drug
Intervention Name(s)
ONO-7684 Placebo
Intervention Description
Placebo comparator
Primary Outcome Measure Information:
Title
Number of participants with clinically significant changes in vital signs (Part A & B)
Description
Pulse rate (bpm), systolic and diastolic blood pressure (mmHg), Respiratory rate (bpm)
Time Frame
Part A: Day 1-4 & Follow-up and Part B: Day 1-15, 17 & Follow up
Title
Number of participants with clinically significant changes observed on 12-lead electrocardiogram (ECG) (Part A & B)
Description
Ventricular rate (beats/min), PR interval (msec), QRS interval (msec), QT (msec), QTcF interval (msec)
Time Frame
Part A: Day 1-4 & Follow up & Part B: Day 1,3,5,7,9,11,14,17 & Follow up
Title
Number of participants with clinically significant changes in cardiac telemetry (Part A only)
Description
Number of participants with cardiac telemetry abnormalities will be reported.
Time Frame
Part A: From 0.5-1 hours pre-dose until 12 hours after dosing at Day 1
Title
Number of participants with clinically significant changes in physical examination (Part A & B)
Description
Number of participants with physical examination abnormalities will be reported.
Time Frame
Part A: Day -1, 1-4 & Follow-up and Part B: Day-1, 1-17 & Follow up
Title
Number of participants with clinically significant changes in laboratory safety tests (haematology, biochemistry and urinalysis) (Part A & B)
Description
Number of participants with abnormalities in laboratory safety tests will be reported.
Time Frame
Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up
Title
Number of participants with adverse events (AE) (Part A & B)
Description
AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time Frame
Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up
Secondary Outcome Measure Information:
Title
Pharmacokinetics (Cmax)
Description
Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 1 and Day 14
Title
Pharmacokinetics (tmax)
Description
Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 1 and Day 14
Title
Pharmacokinetics (AUClast)
Description
Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 14
Title
Pharmacokinetics (AUCinf)
Description
Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 14
Title
Pharmacokinetics (AUCt)
Description
Assessment of the area under the curve of concentration of ONO-7684 and 3-hydroxybenzoic acid - time from zero up to a definitive time, t in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 1
Title
Pharmacokinetics (%AUCextrap)
Description
Assessment of the percentage of AUC∞ extrapolated from tlast to infinity of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 14
Title
Pharmacokinetics (t1/2)
Description
Assessment of the elimination half-time of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 14
Title
Pharmacokinetics (CL/F)
Description
Assessment of the apparent clearance rate of ONO-7684 and 3-hydroxybenzoic acid in Part A only
Time Frame
Day 1 through Day 4
Title
Pharmacokinetics (Terminal Rate Constant)
Description
Assessment of the terminal rate constant (slowest rate constant of the disposition) of ONO-7684 and 3-hydroxybenzoic acid in plasma in Part A only
Time Frame
Day 1 through Day 4
Title
Pharmacokinetics (Aet)
Description
Assessment of the amount of ONO-7684 excreted in urine over the period of sample collection in Part A only
Time Frame
Day 1 through Day 4
Title
Pharmacokinetic (fe/F)
Description
Assessment of the fraction of orally administered ONO-7684 excreted into urine in Part A only
Time Frame
Day 1 through Day 4
Title
Pharmacokinetic (CLr)
Description
Assessment of the renal clearance of ONO-7684 from plasma in Part A only
Time Frame
Day 1 through Day 4
Title
Pharmacokinetic (Ctrough)
Description
Assessment of the trough plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Part B only
Time Frame
Day 1 through Day 14
Title
Pharmacokinetic (AUCtau)
Description
Assessment of the area under the plasma concentration of ONO-7684 and 3-hydroxybenzoic acid -time during a dosing interval in Part B only
Time Frame
Day 14
Title
Pharmacokinetic (CLSS/F)
Description
Assessment of total clearance of ONO-7684 from plasma after oral administration in Part B only
Time Frame
Day 14
Title
Pharmacokinetic (VZ/F)
Description
Assessment of apparent volume of distribution of ONO-7684 after non-intravenous administration calculated at steady state in Part B only
Time Frame
Day 14
Title
Pharmacodynamic (change from baseline in aPTT activity) in serum
Description
Assessment of the effect of ONO-7684 in activated partial thromboplastin time in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
Title
Pharmacodynamic (change from baseline in PT activity) in serum
Description
Assessment of the effect of ONO-7684 in prothrombin time in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
Title
Pharmacodynamic (change from baseline in PT-INR activity) in serum
Description
Assessment of the effect of ONO-7684 in prothrombin time-international normalised ratio in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
Title
Pharmacodynamic (change from baseline in FXIa activity) in serum
Description
Assessment of the effect of ONO-7684 in blood coagulation activated factor XI in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
Title
Pharmacodynamic (correlation of aPTT and FXIa activity) in serum
Description
Assessment of the effect of ONO-7684 in the correlation of activated partial thromboplastin time to blood coagulation activated factor XI in Parts A and B
Time Frame
Part A: Day 1 through Day 4. Part B: Day 1 through Day 17

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18-55 years normotensive male volunteers, or female volunteers of non-childbearing potential (Part B only) body mass index 18.0-30.0 kg/m2 deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine registered with a General Practitioner (GP) in the UK agree to use an effective method of contraception able to give fully informed written consent Exclusion Criteria: Positive tests for hepatitis B & C, HIV severe adverse reaction to any drug sensitivity to trial medication drug or alcohol abuse current smoker or use of nicotine containing products in the previous 6 months vegetarians or vegans, or unwilling to eat a high-fat breakfast (Part A food effect cohorts only) use of strong CYP3A4/5 or P-glycoprotein inhibitors or inducers, anticoagulants, antiplatelet agents, non-steroidal anti-inflammatory drugs and/or acetylsalicylic acid within the previous 30 days prescription or over-the-counter medication, vitamins, herbal treatments or dietary supplements within the previous 7 days (with the exception of paracetamol [acetaminophen]) participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the previous 3 months or plan to donate blood or blood products in the 3 months after the trial vital signs outside the acceptable range clinically relevant abnormal findings at the screening assessment (including creatinine clearance, haemoglobin levels and QTcF) acute or chronic illness clinically relevant abnormal medical history or concurrent medical condition objection by GP possibility that volunteer will not cooperate pre-menopausal females who are pregnant or lactating, or who are of childbearing potential
Facility Information:
Facility Name
Hammersmith Medicines Research (HMR)
City
London
ZIP/Postal Code
NW10 7EW
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers

We'll reach out to this number within 24 hrs